Wedbush Comments on Nuvation Bio Inc.’s FY2026 Earnings (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVBGet Rating) – Investment analysts at Wedbush issued their FY2026 earnings per share (EPS) estimates for Nuvation Bio in a research report issued on Monday, August 1st. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.59) for the year. Wedbush currently has a “Outperform” rating and a $5.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.54) per share.

NUVB has been the topic of several other reports. BMO Capital Markets downgraded Nuvation Bio from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $8.00 to $2.50 in a report on Tuesday. BTIG Research downgraded Nuvation Bio from a “buy” rating to a “neutral” rating in a report on Tuesday. Finally, HC Wainwright started coverage on Nuvation Bio in a report on Wednesday, May 4th. They set a “buy” rating and a $14.00 target price on the stock.

Nuvation Bio Price Performance

NYSE NUVB opened at $2.31 on Wednesday. The firm has a market capitalization of $506.03 million, a P/E ratio of -5.50 and a beta of 0.46. Nuvation Bio has a 1-year low of $2.25 and a 1-year high of $10.45. The business’s 50-day simple moving average is $3.46 and its 200-day simple moving average is $4.99.

Nuvation Bio (NYSE:NUVBGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.05. During the same period last year, the business earned ($0.09) earnings per share.

Institutional Investors Weigh In On Nuvation Bio

A number of institutional investors have recently made changes to their positions in the company. Jane Street Group LLC increased its holdings in shares of Nuvation Bio by 14.4% in the 1st quarter. Jane Street Group LLC now owns 24,362 shares of the company’s stock valued at $128,000 after acquiring an additional 3,070 shares during the last quarter. Raymond James & Associates boosted its position in Nuvation Bio by 28.9% during the 1st quarter. Raymond James & Associates now owns 16,060 shares of the company’s stock valued at $84,000 after purchasing an additional 3,600 shares during the period. Quantbot Technologies LP boosted its position in Nuvation Bio by 147.7% during the 1st quarter. Quantbot Technologies LP now owns 13,383 shares of the company’s stock valued at $70,000 after purchasing an additional 7,981 shares during the period. Candriam Luxembourg S.C.A. boosted its position in Nuvation Bio by 3.1% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 295,935 shares of the company’s stock valued at $2,515,000 after purchasing an additional 8,836 shares during the period. Finally, Pallas Capital Advisors LLC acquired a new position in Nuvation Bio during the 1st quarter valued at approximately $55,000. 70.88% of the stock is currently owned by institutional investors.

About Nuvation Bio

(Get Rating)

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.

Featured Articles

Earnings History and Estimates for Nuvation Bio (NYSE:NUVB)

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with's FREE daily email newsletter.